Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abbott Laboratories
(NY:
ABT
)
118.13
+0.37 (+0.31%)
Official Closing Price
Updated: 7:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results
October 16, 2024
Via
Benzinga
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
October 16, 2024
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend.
Via
MarketBeat
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
October 16, 2024
Abbott Laboratories reported third-quarter 2024 sales of $10.64B, with Medical Devices leading 11.7% sales growth. Adjusted EPS of $1.21 beat analyst expectations. Full-year guidance was updated.
Via
Benzinga
Abbott Labs Earnings Edge Past Q3 Views, Led By Medical Devices
October 16, 2024
Medical devices led organic sales growth.
Via
Investor's Business Daily
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips
October 16, 2024
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
A Glimpse of Abbott Laboratories's Earnings Potential
October 15, 2024
Via
Benzinga
Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock
October 14, 2024
Via
Benzinga
Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
October 16, 2024
Via
Benzinga
Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone
October 16, 2024
Via
Benzinga
Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday
October 16, 2024
Via
Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
October 14, 2024
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.
Via
Talk Markets
Columbus Day: Is Stock Market Open Today?
October 14, 2024
Investors should brace for a busy week with earnings reports from major companies.
Via
Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
October 08, 2024
Via
Benzinga
How Is The Market Feeling About Abbott Laboratories?
October 07, 2024
Via
Benzinga
Navigating 6 Analyst Ratings For Abbott Laboratories
September 26, 2024
Via
Benzinga
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
October 08, 2024
Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion.
Via
Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
October 08, 2024
Via
Benzinga
3 Magnificent Dividend Stocks to Buy in October
October 06, 2024
These dividend stocks are great picks as the fall season gets underway.
Via
The Motley Fool
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades
October 05, 2024
Investors can find market-trouncing blue chip stocks in the healthcare industry.
Via
The Motley Fool
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Down More Than 50%, Is DexCom Stock a Bargain Now?
October 02, 2024
Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market.
Via
The Motley Fool
2 Excellent Dividend Stocks to Buy With Less Than $200
September 28, 2024
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.
Via
The Motley Fool
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
September 25, 2024
These dividend players could lift your portfolio no matter what the market is doing.
Via
The Motley Fool
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst
September 19, 2024
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation.
Via
Benzinga
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
September 19, 2024
Via
Benzinga
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates
September 18, 2024
Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market is divided on the magnitude of the cut, which could trigger significant...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
September 17, 2024
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Can AbbVie Regain Its Status As a Top Dividend Growth Stock?
September 16, 2024
The dividend growth powerhouse is turning the corner.
Via
The Motley Fool
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?
September 16, 2024
The company continues to flex its innovative muscles.
Via
The Motley Fool
3 Stocks to Buy and Hold Forever
September 14, 2024
These stocks are built for the long run.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.